Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fluorine F 18 FP-R01-MG-F2

Radiopharmaceutical · Acts on integrin alphaVbeta6

Early Phase 1 Most advanced trial (none active)
1 Registered trials

What is Fluorine F 18 FP-R01-MG-F2?

Fluorine F 18 FP-R01-MG-F2 is a PET imaging radiotracer made of the R01-MG-F2 cystine knot peptide, an integrin alphaVbeta6 ligand, labeled with [18F]-fluoropropionate. It binds integrin alphaVbeta6-expressing cells so that they can be visualized by positron emission tomography. It is studied in idiopathic pulmonary fibrosis, primary sclerosing cholangitis and Covid19 pneumonia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
[18F]FP-R01-MG-F2
Drug type
Radiopharmaceutical
Targets
integrin alphaVbeta6
Mechanism
Acts on integrin alphaVbeta6
Therapy area
Gastroenterology, Respiratory
In trials of
PLRX
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03183570 Early Phase 1 Idiopathic Pulmonary Fibrosis Completed PLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19 PneumoniaIdiopathic Pulmonary FibrosisPrimary Sclerosing Cholangitis

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.